

## AMENDMENTS TO THE CLAIMS

Claims 1-99. (Canceled)

100. (New) A compound comprising a modified oligonucleotide consisting of 12 to 30 linked nucleosides comprising an at least 8 consecutive nucleobase portion complementary to an equal number of nucleobases of nucleotides 3533-3552 of SEQ ID NO: 4, wherein said modified oligonucleotide is at least 90% complementary to SEQ ID NO: 4.

101. (New) The compound of claim 100, consisting of a single-stranded modified oligonucleotide.

102. (New) The compound of claim 100, wherein said modified oligonucleotide is at least 95% complementary to SEQ ID NO: 4.

103. (New) The compound of claim 100, wherein said modified oligonucleotide is 100% complementary to SEQ ID NO: 4.

104. (New) The compound of claim 101, wherein at least one internucleoside linkage of said modified oligonucleotide is a modified internucleoside linkage.

105. (New) The compound of claim 104, wherein each internucleoside linkage is a phosphorothioate internucleoside linkage.

106. (New) The compound of claim 101, wherein at least one nucleoside comprises a modified sugar.

107. (New) The compound of claim 106, wherein at least one modified sugar is a bicyclic sugar.

108. (New) The compound of claim 106, wherein at least one modified sugar comprises a 2'-O-methoxyethyl.

109. (New) The compound of claim 100, wherein the modified oligonucleotide comprises:

a gap segment consisting of linked deoxynucleosides;

a 5' wing segment consisting of linked nucleosides;

a 3' wing segment consisting of linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment and wherein each nucleoside of each wing segment comprises a modified sugar.

110. (New) The compound of claim 109, wherein the modified oligonucleotide comprises:

a gap segment consisting of ten linked deoxynucleosides;

a 5' wing segment consisting of five linked nucleosides;

a 3' wing segment consisting of five linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment, wherein each nucleoside of each wing segment comprises a 2'-O-methoxyethyl sugar; wherein each cytosine residue of the modified oligonucleotide is a 5-methylcytosine, and wherein each internucleoside linkage of said modified oligonucleotide is a phosphorothioate linkage.

111. (New) The compound of claim 110, wherein the modified oligonucleotide consists of 20 linked nucleosides.

112. (New) The compound of claim 111, wherein the 20 linked nucleosides are complementary to nucleotides 3533-3552 of SEQ ID NO: 4

113. (New) The compound of claim 100, wherein said modified oligonucleotide consists of a nucleobase sequence of SEQ ID NO: 87.

114. (New) The compound of claim 100, wherein said modified oligonucleotide consists of the nucleobase sequence of SEQ ID NO: 87 and comprises:

a gap segment consisting of ten linked deoxynucleosides;

a 5' wing segment consisting of five linked nucleosides;

a 3' wing segment consisting of five linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment, wherein each nucleoside of each wing segment comprises a 2'-O-methoxyethyl sugar,

wherein each internucleoside linkage of said modified oligonucleotide is a phosphorothioate linkage, and wherein each cytosine residue of said modified oligonucleotide is a 5-methylcytosine.

115. (New) A composition comprising a compound of claim 100 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.

116. (New) The composition of claim 115, wherein said modified oligonucleotide consists of the nucleobase sequence of SEQ ID NO: 87 and comprises:

a gap segment consisting of ten linked deoxynucleosides;

a 5' wing segment consisting of five linked nucleosides;

a 3' wing segment consisting of five linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment, wherein each nucleoside of each wing segment comprises a 2'-O-methoxyethyl sugar, wherein each internucleoside linkage of said modified oligonucleotide is a phosphorothioate linkage, and wherein each cytosine residue of said modified oligonucleotide is a 5-methylcytosine.

117. (New) A method of inhibiting the expression of apolipoprotein C-III in cells or tissues comprising contacting said cells or tissues with a therapeutically effective amount of the compound of claim 100 so that expression of apolipoprotein C-III is inhibited.

118. (New) A method of treating an animal having abnormal lipid metabolism comprising administering to said animal a therapeutically effective amount of the compound of claim 100 so that expression of apolipoprotein C-III is inhibited and the animal with abnormal lipid metabolism is treated.

119. (New) A method of modulating glucose levels in an animal comprising administering to said animal a therapeutically effective amount of the compound of claim 100 so that glucose levels in the animal are modulated.

120. (New) A method of lowering cholesterol levels in an animal comprising administering to said animal a therapeutically effective amount of the compound of claim 100 so that cholesterol levels in the animal are lowered.

121. (New) A method of lowering triglyceride levels in an animal comprising administering to said animal a therapeutically effective amount of the compound of claim 100 so that triglyceride levels in the animal are lowered.

122. (New) A method of reducing serum glucose levels in an animal comprising administering to said animal a therapeutically effective amount of the compound of claim 100 so that serum glucose levels in the animal is reduced.

123. (New) A method of decreasing fasted serum insulin levels in an animal comprising administering to said animal a therapeutically effective amount of the compound of claim 100 so that fasted serum insulin levels in the animal are decreased.

124. (New) A method of ameliorating hepatic steatosis in an animal comprising administering to said animal a therapeutically effective amount of the compound of claim 100 so that hepatic steatosis in the animal is ameliorated.

125. (New) A method of lowering liver tissue triglyceride levels in an animal comprising administering to said animal a therapeutically effective amount of the compound of claim 100 so that liver tissue triglyceride levels in the animal are lowered.

126. (New) A modified oligonucleotide consisting of 20 linked nucleosides comprising the nucleobase sequence of SEQ ID NO: 87 and:

a gap segment consisting of ten linked deoxynucleosides;

a 5' wing segment consisting of five linked nucleosides;

a 3' wing segment consisting of five linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment, wherein each nucleoside of each wing segment comprises a 2'-O-methoxyethyl sugar, wherein each internucleoside linkage of said modified oligonucleotide is a phosphorothioate linkage, and wherein each cytosine residue of said modified oligonucleotide is a 5-methylcytosine.